Susquehanna International Group, LLP Biovie Inc. Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$0.4 - $0.56 $9,840 - $13,776	24,601 New	24,601 $9,000
Q4 2023 Feb 14, 2024	BUY	$1.22 - $5.24 $9,553 - $41,034	7,831 Added 67.09%	19,503 $24,000
Q3 2023 Nov 14, 2023	SELL	$2.75 - $5.17 $23,977 - $45,077	-8,719 Reduced 42.76%	11,672 $39,000
Q2 2023 Aug 11, 2023	SELL	$4.09 - $8.29 $505,536 - $1.02 Million	-123,603 Reduced 85.84%	20,391 $87,000
Q1 2023 May 16, 2023	BUY	$4.89 - $10.53 $620,022 - $1.34 Million	126,794 Added 737.17%	143,994 $1.16 Million
Q4 2022 Feb 14, 2023	BUY	$3.86 - $42.0 $66,392 - $722,400	17,200 New	17,200 $133,000
Q1 2022 May 16, 2022	SELL	$2.74 - $5.65 $29,044 - $59,890	-10,600 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.41 - $6.99 $46,746 - $74,094	10,600 New	10,600 $48,000

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $64.3M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.